Ramipril NEW
| Price | $40 | $55 | $82 |
| Package | 50mg | 100mg | 500mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Ramipril | CAS No.: 87333-19-5 |
| Purity: 98.51% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Ramipril |
| Description | Ramipril (Altace) is a long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat. |
| Cell Research | The HUVECs are pretreated with the active metabolites of Ramipril for 24 hours. A serum deprivation method is used to induce apoptosis in the presence of Ramipril for an additional 24 hours. The rate of apoptosis is then determined using flow cytometry with two makers annexinV fluorescein isothiocyanate (FITC+) and propidium iodide (PI).(Only for Reference) |
| In vitro | In spontaneously hypertensive rats, Ramipril significantly inhibits both aortic and pulmonary ACE (ACE Angiotensin Converting Enzyme) activity with an IC50 of approximately 5 mg/kg, without affecting cerebral ACE. When administered slowly, Ramipril lowers blood pressure similar to its effect in vitro on HUVECs (Human Umbilical Vein Endothelial Cells), and compared to other ACE inhibitors, it notably reduces the apoptosis rate induced by lipopolysaccharide. In spontaneously hypertensive rats, Ramipril suppresses systolic blood pressure (SBP) with an IC50 of 1.97 mg/kg. When used in conjunction with AT1 receptor blockers, it synergistically enhances the reduction in SBP. Furthermore, in rats treated with bone morphogenetic protein, Ramipril inhibits beta-cell dysfunction by decreasing monocyte/macrophage permeability, apoptosis, and fibrosis, while also reducing the expression of growth factor genes, the Renin-Angiotensin System (RAS), and inflammatory molecules. |
| In vivo | Long-term treatment of primary human endothelial cells with Ramipril increases ACE expression, an effect that is blocked by the JNK inhibitor SP600125. In serum-starved endothelial cells in vitro, Ramipril does not promote apoptosis. When applied to cultured endothelial cells, Ramipril enhances the activity of CK2 associated with ACE and increases phosphorylation at the ACE Ser1270 site. However, in cells lacking ACE or possessing the S1270A ACE mutation, Ramipril fails to stimulate nuclear accumulation of c-Jun or activate JNK. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (120.05 mM) Ethanol : 41.7 mg/mL (100 mM) |
| Keywords | Ramipril | HOE 498 | Angiotensin-converting Enzyme (ACE) | inhibit | Apoptosis | Inhibitor | HOE498 |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin | Captopril |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Hypertension Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $65.00/1kg |
VIP3Y
|
Hebei Fengjia New Material Co., Ltd
|
2024-09-03 | |
| $1.90/1KG |
VIP4Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2024-08-22 | |
| $0.00/1KG |
VIP1Y
|
Hangzhou Hyper Chemicals Limited
|
2024-06-13 | |
| $0.00/1kg |
VIP1Y
|
Shaanxi TNJONE Pharmaceutical Co., Ltd
|
2024-05-08 | |
| $32.00/1KG |
VIP2Y
|
Henan Fengda Chemical Co., Ltd
|
2024-04-15 | |
| $0.00/1kg |
VIP2Y
|
Hangzhou ICH Biofarm Co., Ltd
|
2023-06-27 | |
| $0.00/1KG |
VIP3Y
|
Henan Aochuang Chemical Co.,Ltd.
|
2022-09-29 | |
| $10.00/1Kg/Bag |
Hebei Zhanyao Biotechnology Co. Ltd
|
2021-11-19 | ||
| $15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-08-11 | ||
| $0.00/1KG |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2021-07-03 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY